Safety and tolerability of high-dose daily vitamin D3 supplementation in the vitamin D and type 2 diabetes (D2d) study-a randomized trial in persons with prediabetes.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

ClinicalTrials.gov NCT01942694, prospectively registered September 16, 2013.

Who Took Part

PubMed indexes the participants as adults.

All participants were included in this analysis.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Incident adverse events (AE) were ascertained 4 times a year at in-person visits (twice a year) and interim remote encounters (twice a year) and were defined as untoward or unfavorable medical occurrences.

What Was Measured

PubMed files the paper under topics including Cholecalciferol, Diabetes Mellitus, Type 2, Dietary Supplements, Hypercalcemia, Hypercalciuria, Nephrolithiasis and Obesity.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (European journal of clinical nutrition), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.